Patricia J. Simner

Johns Hopkins University School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Background Identification of the microorganisms causing infection in children with central nervous system infection is important. Conventional cerebrospinal fluid (CSF) tests may provide limited pathogen detection. CSF metagenomic next-generation sequencing (mNGS) may provide broader pathogen detection in a single assay. Methods Results of CSF mNGS testing performed at Mayo Clinic on patients and nonpatients between January 2024 and June 2025 were retrospectively analyzed. The subcohort of children treated at Mayo Clinic was analyzed to assess test performance as compared with conventional CSF diagnostics and potential clinical impact. Results In total 134 patients (138 CSF mNGS tests) from 22 US states and 2 international sites were included. Overall positivity was 16% with viruses representing most (59%) detections. In the Mayo Clinic subcohort (n = 15), test positivity was 27%: organisms included single detections of Streptococcus mitis group and HIV type 1, as well as 2 detections of Epstein-Barr virus, all confirmed by conventional tests. Positive results were associated with CSF pleocytosis (P = .026). Higher yield was observed in participants whose care was overseen by pediatric infectious diseases (PID) specialists (P = .026) and when a specimen hold strategy was applied (P = .033). Most results (87%) did not alter antimicrobial therapy, with 2 negative results contributing to antimicrobial de-escalation. Conclusions CSF mNGS demonstrated higher diagnostic yield in patients whose specimens showed CSF pleocytosis and in those who had PID consultation. Diagnostic stewardship strategies were applied, including specimen hold approaches and PID consultation.

Year:

2026

C. difficile induces the activation of myeloid cells and IL17-producing lymphoid subsets. Multiparameter flow cytometry analysis of colonic lamina propria innate (myeloid and ILCs) and adaptive immune cell populations of LPL isolated from colons collected at 2 weeks p.i. from GF Apc Min/+ mice gavaged with the 3728T isolates with ( n = 5) or without ( n = 6) C. difficile strain CIm_3728T. Results from two independent experiments. A, Opt-SNE projection of myeloid and ILC populations. B, Dot plots of myeloid cell type abundance as a percentage of the CD45 population. C, Representative gating of DCs, PMN, and IL17 expression by ILC3 cells. D, Opt-SNE projection of adaptive populations (B and T lymphocytes). E, Dot plots of changes in abundance of lymphoid populations with C. difficile . F, Representative gating of lymphoid subsets. Opt-SNE projections are used for visualization purposes only. Statistical analyses in B and E represent Mann–Whitney t tests based on the gating in C and F , respectively. DC, dendritic cells; EILP, early innate lymphoid progenitors; ILC, innate lymphoid cells; IMC, innate myeloid cells; LPL, lamina propria leukocytes; MAC, macrophages; MO, monocytic cells; NK, natural killer; PMN, polymorphonuclear cells; Treg, regulatory T cells.

Year:

2025

C. difficile strains isolated from human colon cancer mucosa drive colonic tumor formation in GF Apc Min/+ mice. A and B, Variation in colonic tumorigenic potential in GF Apc Min/+ mice at 12 to 14 weeks post-inoculation (p.i.) by individual BF-positive tumor (BF + T; A ) or BF-negative tumor (BF − T; B ) colorectal cancer mucosal samples from six patients. n = 6–8 mice per group, from two independent experiments. C, 16S rRNA amplicon sequencing relative abundances of the top 20 species in the six patient tumor slurry inocula and 12 to 14 weeks p.i. stools from mice gavaged with the tumor slurries. D, A consortium of 30 bacterial isolates derived from GF mice gavaged with the 3728T slurry recapitulated colonic tumorigenesis of the original 3728T slurry. n = 5–11 mice per group. E and F, Colonic tumor counts ( E ) and representative methylene blue staining ( F ) of colonic tumors (arrows) at 12 weeks p.i. in a vancomycin/gentamicin model (see Methods) of chronic colonization with nontoxigenic (TcdA − TcdB − ) or toxigenic (TcdA + TcdB + ) C. difficile strains. n = 5–18 mice per group, from two independent experiments. G and H, Colonic tumor counts ( G ) and representative methylene blue staining ( H ) of colonic tumors (arrows) from GF Apc Min/+ mice gavaged with the 3728T isolates with or without the CIm_3728T or CIm_3752T C. difficile strains. n = 6–8 mice per group. I, Colonic tumors induced in GF Apc Min/+ mice gavaged with either the 3979T slurry or the 3979T slurry with C. difficile strain CIm_3728T at 10 weeks p.i. The cross represents a mouse death. n = 7–8 mice per group. Statistical significance was calculated via Kruskal–Wallis followed by Mann–Whitney tests. Mann–Whitney P values are shown. ns, not significant.

Year:

2025

C. difficile –associated tumorigenesis is toxin B (TcdB)–dependent. A, GF Apc Min/+ mice were gavaged with WT or isogenic tcdA − , tcdB − , or tcdA − tcdB − TargeTron mutant strains of M7404, an epidemic strain of ribotype 027, either simultaneously with the 3728T isolates or 1 week later. Tumor counts at 8 weeks p.i. were analyzed. Crosses represent mouse deaths. n = 2–7 mice per group, from two independent experiments. B, Summary graph showing colonic tumor induction of all TcdB − versus TcdB + M7404 strains in combination with the 3728T isolates in GF Apc Min/+ mice. C and D, C. difficile stool CFUs and Vero toxin titers. Mann–Whitney P value is shown. E–M, Experimental design for 2-week experiments with M7404 strains: mice were gavaged with the 3728T isolates − Cd 1 week prior to C. difficile gavage with either the tcdB − ( n = 6 mice) or WT M7404 strain ( n = 8 mice). F and G, C. difficile stool CFUs and toxin titers. H, Representative crypts with BF invasion, stained in red for EUB338 and yellow for Cd198. I, C. difficile tissue invasion. J, Representative H&E images and quantitation of histopathologic changes at 2 weeks p.i. K, Representative images of β-catenin, Ki-67, and PCNA immunofluorescent staining of distal colonic epithelium in M7404 TcdB − (top)– versus M7404 WT (bottom)–inoculated mice. Arrow denotes a dysplastic focus in the M7404 WT–inoculated mouse. L, Quantitation and representative images of crypt depth in the distal colon. M, Host gene expression in colon. Dashed line represents 3728T isolates − Cd-negative control. Statistics shown are Mann–Whitney t tests. ns, not significant.

Year:

2025

C. difficile and the 3728T slurry induce rapid tumorigenesis in GF Apc Min/+ mice despite representing only a fraction of the luminal and mucosal microbiota. A and B, Twenty-five GF Apc Min/+ mice were gavaged with the 3728T slurry; five mice were sacrificed per time point. A, Colonic microadenoma and adenoma counts. B, Hematoxylin and eosin (H&E) staining of a representative microadenoma is shown from a mouse at 2 weeks p.i. (top), whereas a large adenoma coated by a dense BF is shown from a mouse at 4 weeks p.i. (bottom). Confocal imaging of Carnoy's-fixed mouse distal colons stained with the EUB338 universal probe (magenta), Cd198 C. difficile probe (yellow), or DAPI counterstain (blue). White arrows highlight individual C. difficile rods. C and D , Microadenomas ( C ) and FISH staining ( D ) of 2 weeks p.i. distal colons from GF Apc Min/+ mice gavaged with the 3728T isolates ± C. difficile CIm_3728T. Crosses represent mouse deaths. n = 6 mice per group, from two independent experiments. FISH images represent three separate mice per inoculum. White arrowheads denote areas with occasional mucus-invasive BFs directly interacting with epithelium in mice gavaged with the 3728T isolates without C. difficile (3728T isos – Cd). White arrows (bottom) represent areas with crypt-invasive BFs in the mice gavaged with the 3728T isolates + C. difficile . Statistical significance in A and C was calculated via Kruskal–Wallis followed by Mann–Whitney tests. Mann–Whitney P values are shown. E, Relative abundance (RA) of C. difficile derived from 16S rRNA amplicon sequencing of the original human slurry (3728T) or mouse stool obtained at sacrifice of mice in the time course experiment following gavage with the 3728T slurry. dpi, days post-inoculation. F, FISH of the original patient tumor 3728T. CRC, colorectal cancer. G–M, scRNA-seq and gene set enrichment analysis of 3728T slurry ( n = 3)– versus 3979T slurry ( n = 3)–gavaged GF Apc Min/+ mice at 2 weeks p.i. Heat maps depict genes enriched in canonical Wnt ( G ) or ROS ( H ) signaling pathways, with Wilcoxon rank-sum test P values above each gene. I, Inflammatory signaling pathways enriched in specific cell types from 3728T slurry– versus 3979T slurry–gavaged mice at 2 weeks p.i. KEGG, Kyoto Encyclopedia of Genes and Genomes. J, Inhibition and activation of the most significant upstream regulators in either progenitor or differentiated colonocytes. Expression log ratio is an effect size statistic. K and L, Network analysis of transcription factors from IPA upstream regulators enriched in the progenitor cell gene list revealed activation of Wnt/Myc signaling and proliferation, respectively. Lines connect transcription factors with shared target genes in the gene list. Darker lines indicate a greater number of shared target genes. M, Similar network analysis for differentiated colonocytes showed activation of the innate immune response.

Year:

2025

Addressing antimicrobial resistance requires multi-disciplinary action, including from the clinical laboratory. Cascade reporting of the antimicrobial susceptibility test (AST) is a strategy used by some laboratories to nudge clinicians toward the use of more narrow-spectrum antimicrobials. Cascade reporting involves suppression of broader-spectrum antimicrobials if the narrower-spectrum first-line antimicrobials show in-vitro susceptibility. Studies have shown that cascade reporting can reduce use of broad-spectrum antimicrobials and reduce antimicrobial resistance rates. However, implementing cascade reporting can be complex, and some question the effectiveness on impacting long-term prescribing behaviors. Furthermore, there are concerns surrounding compliance and the possible negative impact on public health surveillance for antimicrobial resistance. In this article, experts weigh in on the benefits and risks associated with implementing AST cascade reporting. General consensus is that cascade reporting is a benefit to antimicrobial stewardship, but protocols need careful implementation to minimize risk to patients and public health.

Year:

2025

The carbapenems remain some of the most effective options available for treating patients with serious infections due to Gram-negative bacteria. Carbapenemases are enzymes that hydrolyze carbapenems and are the primary method driving carbapenem resistance globally. Detection of carbapenemases is required for patient management, the rapid implementation of infection prevention and control (IP&C) protocols, and for epidemiologic purposes. Therefore, clinical and public health microbiology laboratories must be able to detect and report carbapenemases among predominant Gram-negative organisms from both cultured isolates and direct from clinical specimens for treatment and surveillance purposes. There is not a “one size fits all” laboratory approach for the detection of bacteria with carbapenemases, and institutions need to determine what fits best with the goals of their antimicrobial stewardship and IP&C programs. Luckily, there are several options and approaches available for clinical laboratories to choose methods that best suits their individual needs. A laboratory approach to detect carbapenemases among bacterial isolates consists of two steps, namely a screening process ( e.g. , not susceptible to ertapenem, meropenem, and/or imipenem), followed by a confirmation test ( i.e. , phenotypic, genotypic or proteomic methods) for the presence of a carbapenemase. Direct from specimen testing for the most common carbapenemases generally involves detection via rapid, molecular approaches. The aim of this article is to provide brief overviews on Gram-negative bacteria carbapenem-resistant definitions, types of carbapenemases, global epidemiology, and then describe in detail the laboratory methods for the detection of carbapenemases among Gram-negative bacteria. We will specifically focus on the Enterobacterales, Pseudomonas aeruginosa , and Acinetobacter baumannii complex.

Year:

2024

Treatment options for carbapenem-resistant gram-negative bacilli (CR-GNB), especially metallo-β-lactamase (MBL)-producing CR-GNB, are limited. Aztreonam (ATM) in combination with avibactam (AVI) has shown potential for treating MBL-producing carbapenem-resistant Enterobacterales (CREs) and Stenotrophomonas maltophilia . However, data on ATM in combination with other β-lactamase inhibitors (BLIs) are limited. We performed a multicenter study to evaluate the in vitro activities of ATM in combination with AVI, vaborbactam (VAB), relebactam (REL), tazobactam (TAZ) as well as with their commercially available formulations against CREs and S. maltophilia using broth microdilution. AVI restored ATM activity for MBL-producing CREs (ATM: 9.8% vs ATM-AVI: 78.0%) and S. maltophilia (ATM: 0% vs ATM-AVI: 93.3%). REL also moderately restored activity of ATM in MBL-producing CREs (ATM: 9.8% vs ATM-REL: 42.7%) and S. maltophilia (ATM: 0% vs ATM-REL: 68.9%). VAB and TAZ demonstrated very limited effect on the activity of ATM against CR-GNB evaluated. The combination of ATM with ceftazidime-AVI (CAZ-AVI) demonstrated maximum activity against CREs. Although ATM-CAZ-AVI is the most potent regimen available for CREs and S. maltophilia , ATM-IMI-REL might be a reasonable alternative.

Year:

2024

There are increasing reports of carbapenem-resistant Enterobacterales (CRE) that test as cefepime-susceptible (S) or susceptible-dose dependent (SDD). However, there are no data to compare the cefepime testing performance of BD Phoenix automated susceptibility system (BD Phoenix) and disk diffusion (DD) relative to reference broth microdilution (BMD) against carbapenemase-producing (CP bla KPC -CRE) and non-producing (non-CP CRE) isolates. Cefepime susceptibility results were interpreted according to CLSI M100Ed32. Essential agreement (EA), categorical agreement (CA), minor errors (miEs), major errors (MEs), and very major errors (VMEs) were calculated for BD Phoenix (NMIC-306 Gram-negative panel) and DD relative to BMD. Correlates were also analyzed by the error rate-bounded method. EA and CA for CP bla KPC -CRE isolates ( n = 64) were 10% for CP bla KPC -CRE and non-CP CRE with BD Phoenix and DD tests. For error rate-bounded method, miEs were <40% for I High + 1 to I Low − 1 ranges for CP bla KPC -CRE and non-CP CRE with BD Phoenix. Regarding disk diffusion, miEs were unacceptable for all MIC ranges among CP bla KPC -CRE. For non-CP CRE isolates, only I High + 1 to I Low − 1 range was acceptable at 37.2%. Using this challenge set of genotypic-phenotypic discordant CRE, the BD Phoenix MICs and DD susceptibility results trended higher (toward SDD and resistant phenotypes) relative to reference BMD results yielding lower CA. These results were more prominent among CP bla KPC -CRE than non-CP CRE.

Year:

2024

Antimicrobial susceptibility test and report guidelines are an important tool for antimicrobial stewardship programs. Since 1972, Tables 1 within the Clinical and Laboratory Standards Institute (CLSI) M100 document have provided a general framework upon which clinical microbiologists and antimicrobial stewardship teams can build algorithms for susceptibility testing and reporting that meet the specific needs of their institution. Many changes were made to Tables 1 in M100-Ed33 to modernize the content to reflect the landscape of current clinical practice, including the growing armamentarium of antimicrobial agents, the emergence of new mechanisms of antimicrobial resistance, the increasing prevalence of infections caused by multidrug-resistant organisms, and updated consensus recommendations for first-choice and alternative agents for treatment. With these items in mind, the CLSI Table 1 ad hoc working group revised Tables 1 with the ultimate goal of supporting institutions in the creation of individualized test and report strategies that support local antimicrobial stewardship program initiatives. These strategies are built on the concepts of selective and cascade reporting. This minireview introduces the concept of CLSI M100-Ed33 Tables 1, describes the changes to Tables 1 introduced in 2023, and provides clinical vignettes that demonstrate how Tables 1 can be used in various scenarios to devise antimicrobial susceptibility test and report strategies.

Year:

2023

Collaborators (13)

Johann D. D. Pitout

University of Calgary

CANADA
View details

Lili Tao

Vanderbilt University Medical Center

UNITED STATES
View details

James T Gaensbauer

University of Colorado School of Medicine

UNITED STATES
View details

franck housseau

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Martha Shrubsole

Research Professor

Vanderbilt University

UNITED STATES
View details

Ken Lau

Associate Professor

Vanderbilt University School of Medicine

UNITED STATES
View details

Cynthia L. Sears

Johns Hopkins University School of Medicine

UNITED STATES
View details

Romney Humphries

Vanderbilt University Medical Center

UNITED STATES
View details

Nicholas Markham

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Christian Jobin

University of Florida

UNITED STATES
View details

Fengyi Wan

Professor

Johns Hopkins University

UNITED STATES
View details

Karen C. Carroll

Johns Hopkins University School of Medicine

UNITED STATES
View details

Robert Coffey

Professor

Vanderbilt University Medical Center

UNITED STATES
View details